Cargando…
Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective ant...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194829/ https://www.ncbi.nlm.nih.gov/pubmed/34122058 http://dx.doi.org/10.3389/fphar.2021.590509 |
_version_ | 1783706445632503808 |
---|---|
author | Kim, Cheorl-Ho |
author_facet | Kim, Cheorl-Ho |
author_sort | Kim, Cheorl-Ho |
collection | PubMed |
description | Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective antiviral agent, like tamiflu against influenza, to block SARS-CoV-2 infection to its host cells, various candidates to mitigate or treat the disease are currently being investigated. Several drugs are being screened for the ability to block virus entry on cell surfaces and/or block intracellular replication in host cells. Vaccine development is being pursued, invoking a better elucidation of the life cycle of the virus. SARS-CoV-2 recognizes O-acetylated neuraminic acids and also several membrane proteins, such as ACE2, as the result of evolutionary switches of O-Ac SA recognition specificities. To provide information related to the current development of possible anti–SARS-COV-2 viral agents, the current review deals with the known inhibitory compounds with low molecular weight. The molecules are mainly derived from natural products of plant sources by screening or chemical synthesis via molecular simulations. Artificial intelligence–based computational simulation for drug designation and large-scale inhibitor screening have recently been performed. Structure–activity relationship of the anti–SARS-CoV-2 natural compounds is discussed. |
format | Online Article Text |
id | pubmed-8194829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81948292021-06-12 Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents Kim, Cheorl-Ho Front Pharmacol Pharmacology Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2), a β-coronavirus, is the cause of the recently emerged pandemic and worldwide outbreak of respiratory disease. Researchers exchange information on COVID-19 to enable collaborative searches. Although there is as yet no effective antiviral agent, like tamiflu against influenza, to block SARS-CoV-2 infection to its host cells, various candidates to mitigate or treat the disease are currently being investigated. Several drugs are being screened for the ability to block virus entry on cell surfaces and/or block intracellular replication in host cells. Vaccine development is being pursued, invoking a better elucidation of the life cycle of the virus. SARS-CoV-2 recognizes O-acetylated neuraminic acids and also several membrane proteins, such as ACE2, as the result of evolutionary switches of O-Ac SA recognition specificities. To provide information related to the current development of possible anti–SARS-COV-2 viral agents, the current review deals with the known inhibitory compounds with low molecular weight. The molecules are mainly derived from natural products of plant sources by screening or chemical synthesis via molecular simulations. Artificial intelligence–based computational simulation for drug designation and large-scale inhibitor screening have recently been performed. Structure–activity relationship of the anti–SARS-CoV-2 natural compounds is discussed. Frontiers Media S.A. 2021-05-27 /pmc/articles/PMC8194829/ /pubmed/34122058 http://dx.doi.org/10.3389/fphar.2021.590509 Text en Copyright © 2021 Kim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Kim, Cheorl-Ho Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title | Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title_full | Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title_fullStr | Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title_full_unstemmed | Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title_short | Anti–SARS-CoV-2 Natural Products as Potentially Therapeutic Agents |
title_sort | anti–sars-cov-2 natural products as potentially therapeutic agents |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194829/ https://www.ncbi.nlm.nih.gov/pubmed/34122058 http://dx.doi.org/10.3389/fphar.2021.590509 |
work_keys_str_mv | AT kimcheorlho antisarscov2naturalproductsaspotentiallytherapeuticagents |